We are live on ! Find out more
ITCI

Intra-Cellular Therapies Inc.
ITCI

Delisted

ITCI was delisted on the 1st of April, 2025.

Back to rankings

4 hedge funds and large institutions have $4.15M invested in Intra-Cellular Therapies Inc. in 2025 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 389 closing their positions.

New
Increased
Maintained
Reduced
Closed

99% less funds holding

Funds holding: 395 → 4 (-391)

100% less capital invested

Capital invested by funds: $13.6B → $4.15M (-$13.6B)

100% less funds holding in top 10

Funds holding in top 10: 52 → 0 (-52)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 389

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
4
Holders Change
-391
Holders Change %
-98.99%
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
-52
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
2
Closed
389
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$1.26B
2
BlackRock
BlackRock
New York
-$1.15B
3
PCM
Pentwater Capital Management
Florida
-$685M
4
HI
HBK Investments
Texas
-$578M
5
Norges Bank
Norges Bank
Norway
-$472M
Name Holding Trade Value Shares
Change 		Change in
Stake
WIC
151
Water Island Capital
New York
– -$5.98M -45,308 Closed
VOYA Investment Management
152
VOYA Investment Management
Georgia
– -$5.82M -44,125 Closed
Pictet Asset Management
153
Pictet Asset Management
Switzerland
– -$5.41M -41,041 Closed
AA
154
ABC Arbitrage
France
– -$5.37M -40,679 Closed
CT
155
ClearAlpha Technologies
Connecticut
– -$5.35M -40,539 Closed
WAM
156
Wolverine Asset Management
Illinois
– -$5.31M -40,265 Closed
ECM
157
Eisler Capital Management
United Kingdom
– -$5.29M -40,092 Closed
YCM
158
Yakira Capital Management
Connecticut
– -$5.16M -39,129 Closed
Two Sigma Advisers
159
Two Sigma Advisers
New York
– -$5.14M -38,967 Closed
Ameriprise
160
Ameriprise
Minnesota
– -$5.14M -38,956 Closed
CG
161
Carmignac Gestion
France
– -$5.12M -38,819 Closed
MC
162
Meteora Capital
Florida
– -$5.04M -38,200 Closed
GI
163
GAMCO Investors
Connecticut
– -$5.03M -38,100 Closed
Dimensional Fund Advisors
164
Dimensional Fund Advisors
Texas
– -$5M -37,873 Closed
PFSRSONJ
165
Police & Firemen's Retirement System of New Jersey
New Jersey
– -$4.93M -37,352 Closed
IC
166
IEQ Capital
California
– -$4.86M -36,845 Closed
Skandinaviska Enskilda Banken (SEB)
167
Skandinaviska Enskilda Banken (SEB)
Sweden
– -$4.62M -35,000 Closed
State of New Jersey Common Pension Fund D
168
State of New Jersey Common Pension Fund D
New Jersey
– -$4.38M -33,199 Closed
JFG
169
Jefferies Financial Group
New York
– -$3.95M -29,909 Closed
Handelsbanken Fonder
170
Handelsbanken Fonder
Sweden
– -$3.87M -29,300 Closed
MS
171
Maven Securities
Jersey
– -$3.83M -29,000 Closed
CL
172
CSS LLC
Illinois
– -$3.81M -28,904 Closed
HHGC
173
Hunting Hill Global Capital
New York
– -$3.67M -27,810 Closed
ASRS
174
Arizona State Retirement System
Arizona
– -$3.62M -27,425 Closed
FC
175
FORA Capital
Florida
– -$3.45M -26,176 Closed
5 6
7
8 9

ITCI Hedge Fund Activity: Q2 2025 in Review

4 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q2 2025, worth a combined $4.15M — down 100% from $13.6B a quarter earlier.

Sellers outnumbered buyers: 389 funds closed out of ITCI and 0 opened new positions — a net loss of 389 holders — while 2 trimmed existing stakes and 0 added.

The largest seller was Vanguard Group, exiting entirely with an estimated $1.26B sold.

  • 4 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q2 2025, down from 395 in Q1 2025.
  • Funds reported $4.15M of Intra-Cellular Therapies Inc. stock for Q2 2025, down 100% quarter-over-quarter.
  • 0 funds opened new Intra-Cellular Therapies Inc. positions in Q2 2025 and 389 closed out, a net change of -389 holders.
  • The largest Intra-Cellular Therapies Inc. seller in Q2 2025 was Vanguard Group, an estimated $1.26B sold.

Based on aggregated 13F filings for Q2 2025.